Cui L X, Ikenami M, Katano H, Takanashi M, Machinami R, Mori S
Department of Pathology, University of Tokyo, Japan.
Pathol Int. 1995 May;45(5):375-82. doi: 10.1111/j.1440-1827.1995.tb03471.x.
B cell non-Hodgkin's lymphoma (B-NHL) occurring in immunocompromised hosts, such as acquired immune deficiency syndrome (AIDS) patients, is a high-grade malignancy resistant to regular chemotherapy. To determine whether immunotherapy with public anti-Ig idiotype antibodies can be used to treat these NHL, the Ig idiotype specificity of six NHL in AIDS patients (AIDS-ML) and 23 B-NHL experimentally induced in immunocompromised mice (SCID mice) was investigated. One of the six AIDS-ML and two of the 23 experimental B-NHL reacted monoclonally with a single public antibody, while one AIDS-ML and three experimental B-NHL reacted polyclonally with two or three different antibodies. The presence of Ig idiotypic polyclonality requires special consideration with regard to the introduction of anti-Ig idiotype immunotherapy in these cases.
发生于免疫功能低下宿主（如获得性免疫缺陷综合征[艾滋病]患者）的B细胞非霍奇金淋巴瘤（B-NHL）是一种对常规化疗耐药的高度恶性肿瘤。为了确定通用抗Ig独特型抗体免疫疗法是否可用于治疗这些非霍奇金淋巴瘤，研究了6例艾滋病患者的非霍奇金淋巴瘤（艾滋病相关淋巴瘤）以及23例在免疫功能低下小鼠（严重联合免疫缺陷小鼠）中实验性诱导的B-NHL的Ig独特型特异性。6例艾滋病相关淋巴瘤中的1例以及23例实验性B-NHL中的2例与一种通用抗体发生单克隆反应，而1例艾滋病相关淋巴瘤和3例实验性B-NHL与两种或三种不同抗体发生多克隆反应。在这些病例中引入抗Ig独特型免疫疗法时，Ig独特型多克隆性的存在需要特别考虑。
